Second quarter sales of the new geographic atrophy drug exceeded expectations, but the company confirmed seven events of retinal vasculitis in patients treated with Syfovre in the real world.

The US biotech’s ANX007 has some analysts cautiously optimistic as post hoc Phase II analyses backed its ability to improve visual acuity in geographic atrophy secondary to age-related macular edema despite a prior primary endpoint miss.

The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.

Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.